Revision 1

#12579Store at -20C

 

Cell Signaling Technology

Orders: 877-616-CELL (2355) [email protected]

Support: 877-678-TECH (8324)

Web: [email protected] cellsignal.com

3 Trask LaneDanversMassachusetts01923USA
For Research Use Only. Not for Use in Diagnostic Procedures.
MW (kDa):

50

UniProt ID:

#P17936

Entrez-Gene Id:

3486

Background

IGFBP3 is a multifunctional protein that plays a key role in regulation of IGFI/II activity, cell proliferation, and death. One of six high-affinity IGF binding proteins, IGFBP3 is the major species in circulation and is bound in a complex with ALS to 99% of hepatic IGF-I (1). Proteolytic degradation of IGFBP3 increases the bioavailability and activity of the IGF I/II (1). However, some biological activities of IGFBP3 are independent of the IGF/IGF-IR axis. IGFBP3 potentiates EGF-induced breast cancer cell proliferation in vitro by enhancing ERK phosphorylation and sphingosine kinase-mediated EGFR trans-activation (2,3). Conversely, IGFBP3 has been shown to induce apoptosis and inhibit NF-κB activity (4).

  1. Jogie-Brahim, S. et al. (2009) Endocr Rev 30, 417-37.
  2. Martin, J.L. et al. (2003) J Biol Chem 278, 2969-76.
  3. Martin, J.L. et al. (2009) J Biol Chem 284, 25542-52.
  4. Han, J. et al. (2011) Cancer Lett 307, 200-10.

Endotoxin

Less than 0.01 ng endotoxin/1 μg hHis6IGFBP3.

Purity

>95% as determined by SDS-PAGE of 6 μg reduced (+) and nonreduced (-) recombinant hHisIGFBP3. All lots are greater than 95% pure.

Source / Purification

Recombinant Human His6IGFBP3 (hHis6IGFBP3) Gly28-Lys291 (Accession #NP_17936) was expressed in human 293 cells at Cell Signaling Technology.

Bioactivity

The bioactivity of hHis6IGFBP3 was determined by inhibition of IGF-I induced AKT phosphorylation in human dermal fibroblasts. The ED50 of each lot is between 2.5-9 ng/ml.

Background

IGFBP3 is a multifunctional protein that plays a key role in regulation of IGFI/II activity, cell proliferation, and death. One of six high-affinity IGF binding proteins, IGFBP3 is the major species in circulation and is bound in a complex with ALS to 99% of hepatic IGF-I (1). Proteolytic degradation of IGFBP3 increases the bioavailability and activity of the IGF I/II (1). However, some biological activities of IGFBP3 are independent of the IGF/IGF-IR axis. IGFBP3 potentiates EGF-induced breast cancer cell proliferation in vitro by enhancing ERK phosphorylation and sphingosine kinase-mediated EGFR trans-activation (2,3). Conversely, IGFBP3 has been shown to induce apoptosis and inhibit NF-κB activity (4).

Background References

    Cross-Reactivity Key

    H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected

    Trademarks and Patents

    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    PathScan is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    Revision 1
    #12579

    Human His6IGFBP3 (hHis6IGFBP3)

    Human His6IGFBP3 (hHis6IGFBP3): Image 1 Expand Image
    The inhibition of IGF-I induced Akt phosphorylation by hHis6IGFBP3. Human dermal fibroblasts were treated with Human Insulin-like Growth Factor I (hIGF-I) # 8917 in the presence or absence of increasing concentrations of hHis6IGFBP3 for 10 minutes, lysed, and Akt1 (Ser473) phosphorylation was quantified using the PathScan® Phospho-Akt1 (Ser473) Sandwich ELISA Kit #7160.
    Human His6IGFBP3 (hHis6IGFBP3): Image 2 Expand Image
    The purity of recombinant hHis6 IGFBP3 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant

    hHis6 IGFBP3 and staining overnight with Coomassie Blue.